FILGRASTIM
Muscular Atrophy, Spinal
Kaohsiung Medical University Chung-Ho Memorial Hospitalprotein_peptidePhase 2/3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Muscular Atrophy, Spinal cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Risdiplam Scholar Rock, Inc. | Phase 4 | A |
Hydroxyurea Kaohsiung Medical University Chung-Ho Memorial Hospital | Phase 2/3 | BB |
Salanersen Biogen | Phase 3 | B |
Somatotropin University Hospital Freiburg | Phase 2 | B |
OLESOXIME, E- Hoffmann-La Roche | Phase 2 | B |
View all 10 →
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →